{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:37:38Z","timestamp":1763037458471,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Few studies have measured frailty as a potential reason for foregoing transcatheter aortic valve replacement (TAVR) in older adults with severe aortic stenosis (AS). This study sought to determine the impact of frailty and other clinician-cited reasons on restricted mean survival time (RMST).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>An analysis of the McGill Frailty Registry was conducted between 2014 and 2018 at the McGill University Health Center Structural Valve Clinic. Consecutive nonsurgical patients referred for TAVR were included. In those that underwent balloon aortic valvuloplasty or medical management, the primary clinician-cited reason for foregoing TAVR was codified. Vital status was ascertained at 1\u2009year and analysed using RMST and Kaplan-Meier analyses.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The study consisted of 373 patients with a mean age of 82.4\u2009years, of which 233 underwent TAVR and 140 did not. Patients who did not undergo TAVR were more likely to be nonagenarians, with left ventricular dysfunction, chronic kidney disease, dementia, disability, depression, malnutrition, and frailty. The primary clinician-cited reason was: comorbidity in 34%, frailty in 23%, procedural feasibility and risks in 16%, and mild or unrelated symptoms in 27%. Compared to the TAVR group, 1-year RMST was reduced by 2.0\u2009months in the medical management group (95% CI 1.2, 2.7) and by 1.1\u2009months in the valvuloplasty group (95% CI -0.2, 2.5).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Patients with severe AS referred for TAVR may never undergo the procedure on the basis of comorbidity, frailty, procedural issues, and symptoms. The best treatment decision is one that follows from multi-disciplinary assessment encompassing frailty.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12872-020-01572-4","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T11:02:59Z","timestamp":1592478179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Restricted mean survival time of older adults with severe aortic stenosis referred for transcatheter aortic valve replacement"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9601-4161","authenticated-orcid":false,"given":"Julia","family":"Rodighiero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolo","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Martucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Spaziano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Lachapelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"de Varennes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Claude","family":"Ouimet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Afilalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Transcatheter Aortic Valve Replacement | CADTH.ca. https:\/\/cadth.ca\/transcatheter-aortic-valve-replacement-3. Accessed January 15, 2020.","key":"1572_CR1","DOI":"10.33290\/jtvt.ra.20-2005"},{"key":"1572_CR2","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","volume":"363","author":"MB Leon","year":"2010","unstructured":"Leon MB, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597\u2013607.","journal-title":"N Engl J Med"},{"key":"1572_CR3","first-page":"1","volume":"43","author":"C Galatas","year":"2019","unstructured":"Galatas C, Afilalo J. Transcatheter aortic valve replacement over age 90: risks vs benefits. Clin Cardiol. 2019;43:1\u20137.","journal-title":"Clin Cardiol"},{"key":"1572_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jacc.2017.06.024","volume":"70","author":"J Afilalo","year":"2017","unstructured":"Afilalo J, et al. Frailty assessment in older adults undergoing Transcatheter or surgical aortic valve replacement: the frailty-AVR study. J Am Coll Cardiol. 2017;70:689\u2013700.","journal-title":"J Am Coll Cardiol"},{"key":"1572_CR5","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1016\/j.jacc.2019.08.1034","volume":"74","author":"J Gregson","year":"2019","unstructured":"Gregson J, et al. Nonproportional hazards for time-to-event outcomes in clinical trials: JACC review topic of the week. J Am Coll Cardiol. 2019;74:2102\u201312.","journal-title":"J Am Coll Cardiol"},{"key":"1572_CR6","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.jtcvs.2008.12.030","volume":"137","author":"SR Kapadia","year":"2009","unstructured":"Kapadia SR, et al. Characterization and outcome of patients with severe symptomatic aortic stenosis referred for percutaneous aortic valve replacement. J Thorac Cardiovasc Surg. 2009;137:1430\u20135.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1572_CR7","first-page":"533","volume":"2","author":"DS Bach","year":"2009","unstructured":"Bach DS, et al. Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement. Circulation. 2009;2:533\u20139.","journal-title":"Circulation"},{"key":"1572_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1308\/003588412X13171221591817","volume":"94","author":"A Badran","year":"2012","unstructured":"Badran A, Vohra H, Livesey S. Unoperated severe aortic stenosis: decision making in an adult UK-based population. Ann R Coll Surg Engl. 2012;94:416\u201321.","journal-title":"Ann R Coll Surg Engl"},{"key":"1572_CR9","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1136\/heartjnl-2017-312304","volume":"104","author":"RJ Everett","year":"2018","unstructured":"Everett RJ, Clavel M-A, Pibarot P, Dweck MR. Timing of intervention in aortic stenosis: a review of current and future strategies. Heart. 2018;104:2067\u201376.","journal-title":"Heart."},{"key":"1572_CR10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.amjcard.2015.06.014","volume":"116","author":"D Kang","year":"2015","unstructured":"Kang D, et al. Mortality predictors in patients referred for but not undergoing Transcatheter aortic valve replacement. Am J Cardiol. 2015;116:919\u201324.","journal-title":"Am J Cardiol"},{"key":"1572_CR11","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1016\/j.jacc.2019.03.496","volume":"73","author":"M Szerlip","year":"2019","unstructured":"Szerlip M, et al. Transcatheter aortic valve replacement in patients with end-stage renal disease. J Am Coll Cardiol. 2019;73:2806\u201315.","journal-title":"J Am Coll Cardiol"},{"key":"1572_CR12","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jacc.2013.04.057","volume":"62","author":"M Yamamoto","year":"2013","unstructured":"Yamamoto M, et al. Prognostic value of chronic kidney disease after Transcatheter aortic valve implantation. J Am Coll Cardiol. 2013;62:869\u201377.","journal-title":"J Am Coll Cardiol"},{"key":"1572_CR13","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.jcin.2017.07.044","volume":"10","author":"T Gupta","year":"2017","unstructured":"Gupta T, et al. Association of Chronic Kidney Disease with in-hospital outcomes of Transcatheter aortic valve replacement. J Am Coll Cardiol Intv. 2017;10:2050\u201360.","journal-title":"J Am Coll Cardiol Intv"},{"key":"1572_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2459\/JCM.0000000000000777","volume":"20","author":"H Takagi","year":"2019","unstructured":"Takagi H, et al. Meta-analysis of impact of liver disease on mortality after transcatheter aortic valve implantation. J Cardiovasc Med. 2019;20:237\u201344.","journal-title":"J Cardiovasc Med"},{"key":"1572_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jacc.2016.04.057","volume":"68","author":"JB Hermiller","year":"2016","unstructured":"Hermiller JB, et al. Predicting early and late mortality after Transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;68:343\u201352.","journal-title":"J Am Coll Cardiol"},{"key":"1572_CR16","doi-asserted-by":"publisher","first-page":"e009195","DOI":"10.1161\/JAHA.118.009195","volume":"7","author":"T Shimura","year":"2018","unstructured":"Shimura T, et al. Patients refusing Transcatheter aortic valve replacement even once have poorer clinical outcomes. J Am Heart Assoc. 2018;7:e009195.","journal-title":"J Am Heart Assoc"},{"key":"1572_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ccl.2019.09.011","volume":"38","author":"P Piankova","year":"2020","unstructured":"Piankova P, Afilalo J. Prevalence and prognostic implications of frailty in Transcatheter aortic valve replacement. Cardiol Clin. 2020;38:75\u201387.","journal-title":"Cardiol Clin"},{"key":"1572_CR18","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cjca.2019.08.011","volume":"35","author":"AW Asgar","year":"2019","unstructured":"Asgar AW, et al. 2019 Canadian cardiovascular society position statement for Transcatheter aortic valve implantation. Can J Cardiol. 2019;35:1437\u201348.","journal-title":"Can J Cardiol"},{"key":"1572_CR19","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1001\/jamacardio.2017.2922","volume":"2","author":"DH Kim","year":"2017","unstructured":"Kim DH, Uno H, Wei L-J. Restricted mean survival time as a measure to interpret clinical trial results. JAMA Cardiol. 2017;2:1179\u201380.","journal-title":"JAMA Cardiol"},{"key":"1572_CR20","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1161\/01.CIR.89.2.642","volume":"89","author":"CM Otto","year":"1994","unstructured":"Otto CM, et al. Three-year outcome after balloon aortic valvuloplasty. Insights into prognosis of valvular aortic stenosis. Circulation. 1994;89:642\u201350.","journal-title":"Circulation."},{"key":"1572_CR21","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/0735-1097(95)00363-0","volume":"26","author":"EB Lieberman","year":"1995","unstructured":"Lieberman EB, et al. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. J Am Coll Cardiol. 1995;26:1522\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1572_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jcin.2014.08.015","volume":"8","author":"S Kapadia","year":"2015","unstructured":"Kapadia S, et al. Outcomes of inoperable symptomatic aortic stenosis patients not undergoing aortic valve replacement: insight into the impact of balloon aortic Valvuloplasty from the PARTNER trial (placement of AoRtic TraNscathetER valve trial). J Am Coll Cardiol Intv. 2015;8:324\u201333.","journal-title":"J Am Coll Cardiol Intv"},{"key":"1572_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40471-019-0180-5","volume":"6","author":"RW Platt","year":"2019","unstructured":"Platt RW, Hutcheon JA, Suissa S. Immortal time bias in epidemiology. Curr Epidemiol Rep. 2019;6:23\u20137.","journal-title":"Curr Epidemiol Rep"},{"key":"1572_CR24","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jacc.2016.12.006","volume":"69","author":"CM Otto","year":"2017","unstructured":"Otto CM, et al. 2017 ACC expert consensus decision pathway for Transcatheter aortic valve replacement in the Management of Adults with aortic stenosis: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2017;69:1313\u201346.","journal-title":"J Am Coll Cardiol"},{"unstructured":"Aortic Stenosis: TAVR\/SAVR. https:\/\/www.cardiosmart.org\/SDM\/Decision-Aids\/Find-Decision-Aids\/Aortic-Stenosis. Accessed 17 Jan 2020.","key":"1572_CR25"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01572-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-020-01572-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01572-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T23:11:46Z","timestamp":1623971506000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-020-01572-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1572"],"URL":"https:\/\/doi.org\/10.1186\/s12872-020-01572-4","relation":{},"ISSN":["1471-2261"],"issn-type":[{"type":"electronic","value":"1471-2261"}],"subject":[],"published":{"date-parts":[[2020,6,18]]},"assertion":[{"value":"3 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study involved human participants and was granted approval was by the McGill University Health Centre Research Ethics Board (reference number: FWA00000840- FWA00000845.IRB00010120, study number: 2013\u20132097).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Rodighiero J, none; Piazza, none; Martucci, none; Spaziano, none; Lachapelle, none; de Varennes, none; Ouimet, none; Afilalo, none.The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"299"}}